Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	chromo shadow domain binding	SP100 ATRX	1.07e-04	6	54	2	GO:0070087
GeneOntologyMolecularFunction	translation initiation factor binding	EIF2AK4 EIF3C EIF3CL	1.59e-04	39	54	3	GO:0031369
GeneOntologyMolecularFunction	basal RNA polymerase II transcription machinery binding	PCF11 TCF4 LEO1	7.58e-04	66	54	3	GO:0001099
GeneOntologyMolecularFunction	basal transcription machinery binding	PCF11 TCF4 LEO1	7.58e-04	66	54	3	GO:0001098
GeneOntologyBiologicalProcess	cytoplasmic translational initiation	NCBP1 EIF2AK4 EIF3C EIF3CL	4.23e-06	45	50	4	GO:0002183
GeneOntologyBiologicalProcess	cerebellar cortex morphogenesis	LHX1 USP9X HERC1 AGTPBP1	5.49e-06	48	50	4	GO:0021696
GeneOntologyBiologicalProcess	cerebellar Purkinje cell differentiation	LHX1 HERC1 AGTPBP1	1.07e-05	18	50	3	GO:0021702
GeneOntologyBiologicalProcess	cerebellum morphogenesis	LHX1 USP9X HERC1 AGTPBP1	1.35e-05	60	50	4	GO:0021587
GeneOntologyBiologicalProcess	cerebellar Purkinje cell layer formation	LHX1 HERC1 AGTPBP1	1.48e-05	20	50	3	GO:0021694
GeneOntologyBiologicalProcess	hindbrain morphogenesis	LHX1 USP9X HERC1 AGTPBP1	1.74e-05	64	50	4	GO:0021575
GeneOntologyBiologicalProcess	cerebellar cortex development	LHX1 USP9X HERC1 AGTPBP1	2.63e-05	71	50	4	GO:0021695
GeneOntologyBiologicalProcess	cerebellar Purkinje cell layer morphogenesis	LHX1 HERC1 AGTPBP1	2.97e-05	25	50	3	GO:0021692
GeneOntologyBiologicalProcess	oviduct epithelium development	LHX1 C3	5.73e-05	5	50	2	GO:0035846
GeneOntologyBiologicalProcess	cytoplasmic translation	NEMF NCBP1 EIF2AK4 EIF3C EIF3CL	5.95e-05	172	50	5	GO:0002181
GeneOntologyBiologicalProcess	cell differentiation in hindbrain	LHX1 HERC1 AGTPBP1	6.33e-05	32	50	3	GO:0021533
GeneOntologyBiologicalProcess	cerebellar cortex formation	LHX1 HERC1 AGTPBP1	7.61e-05	34	50	3	GO:0021697
GeneOntologyBiologicalProcess	regulation of transcription elongation by RNA polymerase II	INTS14 LEO1 SUPT6H NCBP1	7.61e-05	93	50	4	GO:0034243
GeneOntologyBiologicalProcess	positive regulation of RNA binding	NCBP1 EIF3C	8.59e-05	6	50	2	GO:1905216
GeneOntologyBiologicalProcess	RNA 3'-end processing	PCF11 INTS14 LEO1 NCBP1	9.33e-05	98	50	4	GO:0031123
GeneOntologyBiologicalProcess	cerebellar Purkinje cell layer development	LHX1 HERC1 AGTPBP1	1.15e-04	39	50	3	GO:0021680
GeneOntologyBiologicalProcess	oviduct development	LHX1 C3	1.20e-04	7	50	2	GO:0060066
GeneOntologyBiologicalProcess	regulation of DNA-templated transcription elongation	INTS14 LEO1 SUPT6H NCBP1	1.22e-04	105	50	4	GO:0032784
GeneOntologyBiologicalProcess	regulation of RNA binding	NCBP1 EIF3C	1.60e-04	8	50	2	GO:1905214
GeneOntologyBiologicalProcess	mRNA 3'-end processing	PCF11 LEO1 NCBP1	1.89e-04	46	50	3	GO:0031124
GeneOntologyBiologicalProcess	DNA metabolic process	SP100 CHAF1B TADA1 ATRX SUPT6H USP9X CECR2 TSPYL2 CLSPN TFRC	2.26e-04	1081	50	10	GO:0006259
GeneOntologyBiologicalProcess	transcription elongation by RNA polymerase II	INTS14 LEO1 SUPT6H NCBP1	2.54e-04	127	50	4	GO:0006368
GeneOntologyBiologicalProcess	translational initiation	NCBP1 EIF2AK4 EIF3C EIF3CL	2.94e-04	132	50	4	GO:0006413
GeneOntologyBiologicalProcess	positive regulation of transcription elongation by RNA polymerase II	LEO1 SUPT6H NCBP1	3.05e-04	54	50	3	GO:0032968
GeneOntologyBiologicalProcess	cerebellum development	LHX1 USP9X HERC1 AGTPBP1	3.58e-04	139	50	4	GO:0021549
GeneOntologyBiologicalProcess	nucleosome organization	CHAF1B ATRX SUPT6H TSPYL2	3.88e-04	142	50	4	GO:0034728
GeneOntologyBiologicalProcess	DNA-templated transcription elongation	INTS14 LEO1 SUPT6H NCBP1	4.09e-04	144	50	4	GO:0006354
GeneOntologyBiologicalProcess	positive regulation of DNA-templated transcription, elongation	LEO1 SUPT6H NCBP1	4.58e-04	62	50	3	GO:0032786
GeneOntologyBiologicalProcess	metencephalon development	LHX1 USP9X HERC1 AGTPBP1	5.14e-04	153	50	4	GO:0022037
GeneOntologyBiologicalProcess	formation of cytoplasmic translation initiation complex	EIF3C EIF3CL	5.93e-04	15	50	2	GO:0001732
GeneOntologyBiologicalProcess	anatomical structure formation involved in morphogenesis	LHX1 TCF4 SP100 LEO1 SUPT6H CECR2 EQTN C3 C5 HERC1 AGTPBP1	7.02e-04	1483	50	11	GO:0048646
GeneOntologyBiologicalProcess	glomerulus development	LHX1 C5 PLCE1	8.64e-04	77	50	3	GO:0032835
GeneOntologyBiologicalProcess	regulation of immunoglobulin mediated immune response	SUPT6H C3 TFRC	9.31e-04	79	50	3	GO:0002889
GeneOntologyBiologicalProcess	regulation of B cell mediated immunity	SUPT6H C3 TFRC	9.31e-04	79	50	3	GO:0002712
GeneOntologyBiologicalProcess	complement activation, alternative pathway	C3 C5	9.59e-04	19	50	2	GO:0006957
GeneOntologyBiologicalProcess	nuclear export	SP100 SUPT6H NEMF NCBP1	1.05e-03	185	50	4	GO:0051168
GeneOntologyCellularComponent	eukaryotic translation initiation factor 3 complex, eIF3m	EIF3C EIF3CL	2.98e-04	9	61	2	GO:0071541
GeneOntologyCellularComponent	transcription elongation factor complex	LEO1 SUPT6H ICE1	5.87e-04	56	61	3	GO:0008023
GeneOntologyCellularComponent	eukaryotic translation initiation factor 3 complex	EIF3C EIF3CL	9.79e-04	16	61	2	GO:0005852
GeneOntologyCellularComponent	eukaryotic 48S preinitiation complex	EIF3C EIF3CL	1.24e-03	18	61	2	GO:0033290
GeneOntologyCellularComponent	eukaryotic 43S preinitiation complex	EIF3C EIF3CL	1.39e-03	19	61	2	GO:0016282
GeneOntologyCellularComponent	translation preinitiation complex	EIF3C EIF3CL	1.54e-03	20	61	2	GO:0070993
HumanPheno	Triangular nasal tip	TCF4 ATRX	1.78e-05	2	22	2	HP:0000451
Domain	NBPF_dom	NBPF15 NBPF9 NBPF11 NBPF14 NBPF1	6.91e-11	11	53	5	IPR010630
Domain	NBPF	NBPF15 NBPF9 NBPF11 NBPF14 NBPF1	6.91e-11	11	53	5	PS51316
Domain	DUF1220	NBPF15 NBPF9 NBPF11 NBPF14 NBPF1	6.91e-11	11	53	5	PF06758
Domain	DUF1220	NBPF15 NBPF9 NBPF11 NBPF1	7.20e-09	9	53	4	SM01148
Domain	EIF3C_N_dom	EIF3C EIF3CL	7.90e-06	2	53	2	IPR008905
Domain	eIF-3c_N	EIF3C EIF3CL	7.90e-06	2	53	2	PF05470
Domain	EIF3C	EIF3C EIF3CL	7.90e-06	2	53	2	IPR027516
Domain	-	C3 C5	4.72e-05	4	53	2	1.20.91.20
Domain	Anaphylatoxin_comp_syst	C3 C5	7.86e-05	5	53	2	IPR018081
Domain	Anaphylatoxn_comp_syst_dom	C3 C5	7.86e-05	5	53	2	IPR001840
Domain	ANATO	C3 C5	1.64e-04	7	53	2	SM00104
Domain	ANATO	C3 C5	1.64e-04	7	53	2	PF01821
Domain	ANAPHYLATOXIN_2	C3 C5	1.64e-04	7	53	2	PS01178
Domain	ANAPHYLATOXIN_1	C3 C5	1.64e-04	7	53	2	PS01177
Domain	Anaphylatoxin/fibulin	C3 C5	1.64e-04	7	53	2	IPR000020
Domain	A2M_N_2	C3 C5	2.19e-04	8	53	2	SM01359
Domain	-	C3 C5	2.19e-04	8	53	2	2.60.40.690
Domain	A2M_recep	C3 C5	2.19e-04	8	53	2	SM01361
Domain	A2M	C3 C5	2.19e-04	8	53	2	SM01360
Domain	A2M_N	C3 C5	3.50e-04	10	53	2	PF01835
Domain	A2M_N	C3 C5	3.50e-04	10	53	2	IPR002890
Domain	A-macroglobulin_rcpt-bd	C3 C5	3.50e-04	10	53	2	IPR009048
Domain	ALPHA_2_MACROGLOBULIN	C3 C5	3.50e-04	10	53	2	PS00477
Domain	A2M	C3 C5	3.50e-04	10	53	2	PF00207
Domain	A2M_N_2	C3 C5	3.50e-04	10	53	2	IPR011625
Domain	A2M_comp	C3 C5	3.50e-04	10	53	2	IPR011626
Domain	A2M_N_2	C3 C5	3.50e-04	10	53	2	PF07703
Domain	A2M_recep	C3 C5	3.50e-04	10	53	2	PF07677
Domain	A2M_comp	C3 C5	3.50e-04	10	53	2	PF07678
Domain	Macroglobln_a2	C3 C5	3.50e-04	10	53	2	IPR001599
Domain	-	C3 C5	5.12e-04	12	53	2	1.50.10.20
Domain	PINT	EIF3C EIF3CL	9.24e-04	16	53	2	SM00088
Domain	C345C	C3 C5	1.05e-03	17	53	2	SM00643
Domain	PCI_dom	EIF3C EIF3CL	1.05e-03	17	53	2	IPR000717
Domain	PCI	EIF3C EIF3CL	1.05e-03	17	53	2	PF01399
Domain	Terpenoid_cyclase/PrenylTrfase	C3 C5	1.17e-03	18	53	2	IPR008930
Domain	NTR	C3 C5	1.31e-03	19	53	2	PF01759
Domain	Netrin_module_non-TIMP	C3 C5	1.31e-03	19	53	2	IPR018933
Domain	NTR	C3 C5	1.92e-03	23	53	2	PS50189
Domain	Netrin_domain	C3 C5	1.92e-03	23	53	2	IPR001134
Domain	TIMP-like_OB-fold	C3 C5	2.46e-03	26	53	2	IPR008993
Pathway	REACTOME_RNA_POLYMERASE_II_TRANSCRIBES_SNRNA_GENES	PCF11 INTS14 NCBP1 ICE1	7.01e-05	73	43	4	MM15349
Pathway	WP_ENDODERM_DIFFERENTIATION	LHX1 TCF4 ZBTB17 LEO1 ZFHX4	7.07e-05	143	43	5	M39591
Pathway	REACTOME_RNA_POLYMERASE_II_TRANSCRIBES_SNRNA_GENES	PCF11 INTS14 NCBP1 ICE1	1.05e-04	81	43	4	M27647
Pathway	REACTOME_ACTIVATION_OF_C3_AND_C5	C3 C5	1.89e-04	7	43	2	MM14685
Pathway	BIOCARTA_ALTERNATIVE_PATHWAY	C3 C5	2.52e-04	8	43	2	MM1582
Pathway	REACTOME_ACTIVATION_OF_C3_AND_C5	C3 C5	2.52e-04	8	43	2	M27031
Pathway	BIOCARTA_ALTERNATIVE_PATHWAY	C3 C5	3.23e-04	9	43	2	M22072
Pathway	WP_ACQUIRED_PARTIAL_LIPODYSTROPHY_BARRAQUERSIMONS_SYNDROME	C3 C5	4.03e-04	10	43	2	M42576
Pathway	BIOCARTA_LECTIN_PATHWAY	C3 C5	4.91e-04	11	43	2	MM1430
Pathway	WP_COMPLEMENTMEDIATED_INFLAMMATION_OF_PULMONARY_ALVEOLUS_IN_COVID19_HYPOTHETICAL_PATHWAY	C3 C5	5.88e-04	12	43	2	M48316
Pathway	BIOCARTA_CLASSIC_PATHWAY	C3 C5	5.88e-04	12	43	2	MM1368
Pathway	BIOCARTA_LECTIN_PATHWAY	C3 C5	6.94e-04	13	43	2	M4732
Pathway	REACTOME_FORMATION_OF_RNA_POL_II_ELONGATION_COMPLEX	LEO1 SUPT6H NCBP1	7.26e-04	58	43	3	M805
Pathway	REACTOME_FORMATION_OF_RNA_POL_II_ELONGATION_COMPLEX	LEO1 SUPT6H NCBP1	7.63e-04	59	43	3	MM14504
Pathway	BIOCARTA_CLASSIC_PATHWAY	C3 C5	9.31e-04	15	43	2	M7146
Pathway	WP_CELLS_AND_MOLECULES_INVOLVED_IN_LOCAL_ACUTE_INFLAMMATORY_RESPONSE	C3 C5	1.20e-03	17	43	2	M39733
Pathway	WP_COMPLEMENT_ACTIVATION_CLASSICAL_PATHWAY	C3 C5	1.20e-03	17	43	2	MM15944
Pathway	BIOCARTA_LAIR_PATHWAY	C3 C5	1.20e-03	17	43	2	M3952
Pathway	BIOCARTA_COMP_PATHWAY	C3 C5	1.20e-03	17	43	2	MM1369
Pathway	REACTOME_PROCESSING_OF_INTRONLESS_PRE_MRNAS	PCF11 NCBP1	1.67e-03	20	43	2	M497
Pathway	REACTOME_PROCESSING_OF_INTRONLESS_PRE_MRNAS	PCF11 NCBP1	1.67e-03	20	43	2	MM15469
Pathway	BIOCARTA_COMP_PATHWAY	C3 C5	1.67e-03	20	43	2	M917
Pathway	REACTOME_RNA_POLYMERASE_II_PRE_TRANSCRIPTION_EVENTS	LEO1 SUPT6H NCBP1	1.91e-03	81	43	3	M865
Pathway	WP_COMPLEMENT_ACTIVATION	C3 C5	2.02e-03	22	43	2	M39502
Pathway	REACTOME_RNA_POLYMERASE_II_PRE_TRANSCRIPTION_EVENTS	LEO1 SUPT6H NCBP1	2.05e-03	83	43	3	MM15314
Pubmed	A novel gene family NBPF: intricate structure generated by gene duplications during primate evolution.	NBPF8 NBPF19 NBPF15 NBPF12 NBPF9 NBPF10 NBPF11 NBPF14 NBPF1	2.45e-20	21	61	9	16079250
Pubmed	Evolutionary history and genome organization of DUF1220 protein domains.	NBPF8 NBPF15 NBPF12 NBPF9 NBPF14 NBPF1	4.72e-15	10	61	6	22973535
Pubmed	Why do cellular proteins linked to K63-polyubiquitin chains not associate with proteasomes?	NBPF8 NBPF12 NBPF9 NBPF10 NBPF11 NBPF14 HYDIN NBPF1	6.52e-10	170	61	8	23314748
Pubmed	New interaction partners for Nek4.1 and Nek4.2 isoforms: from the DNA damage response to RNA splicing.	NBPF8 NBPF15 NBPF12 NBPF9 NBPF10 SRPK1 NBPF11 NBPF14 AGTPBP1 NBPF1	2.05e-08	513	61	10	25798074
Pubmed	The mammalian heterochromatin protein 1 binds diverse nuclear proteins through a common motif that targets the chromoshadow domain.	SP100 CHAF1B ATRX	1.45e-06	13	61	3	15882967
Pubmed	Chr21 protein-protein interactions: enrichment in proteins involved in intellectual disability, autism, and late-onset Alzheimer's disease.	CHAF1B LEO1 ATRX ZNF532 CNST USP9X DDX18 NEMF TSPYL2 NCBP1 EIF3C AGTPBP1	2.01e-06	1285	61	12	35914814
Pubmed	Complement-mediated macrophage polarization in perivascular adipose tissue contributes to vascular injury in deoxycorticosterone acetate-salt mice.	C3 C5	3.03e-06	2	61	2	25573852
Pubmed	Constitutional translocation t(1;17)(p36.31-p36.13;q11.2-q12.1) in a neuroblastoma patient. Establishment of somatic cell hybrids and identification of PND/A12M2 on chromosome 1 and NF1/SCYA7 on chromosome 17 as breakpoint flanking single copy markers.	NBPF11 NBPF1	3.03e-06	2	61	2	7700633
Pubmed	Alterations in plasma complement levels after human ischemic stroke.	C3 C5	3.03e-06	2	61	2	16823297
Pubmed	C1q is elevated during chronic Staphylococcus epidermidis central nervous system catheter infection.	C3 C5	3.03e-06	2	61	2	38881889
Pubmed	Hyperfunctional complement C3 promotes C5-dependent atypical hemolytic uremic syndrome in mice.	C3 C5	3.03e-06	2	61	2	30714990
Pubmed	Complement factor C5 but not C3 contributes significantly to hydrosalpinx development in mice infected with Chlamydia muridarum.	C3 C5	3.03e-06	2	61	2	24842924
Pubmed	Human skin mast cells express complement factors C3 and C5.	C3 C5	3.03e-06	2	61	2	23833239
Pubmed	C3a and C5a are chemotactic factors for human mesenchymal stem cells, which cause prolonged ERK1/2 phosphorylation.	C3 C5	3.03e-06	2	61	2	19265162
Pubmed	Copy number variations and gene polymorphisms of complement components in ocular Behcet's disease and Vogt-Koyanagi-Harada syndrome.	C3 C5	3.03e-06	2	61	2	26269006
Pubmed	Acute lung injury induced by lipopolysaccharide is independent of complement activation.	C3 C5	3.03e-06	2	61	2	18490769
Pubmed	Complement effectors, C5a and C3a, in cystic fibrosis lung fluid correlate with disease severity.	C3 C5	3.03e-06	2	61	2	28278205
Pubmed	Intravascular clearance of disseminating Cryptococcus neoformans in the brain can be improved by enhancing neutrophil recruitment in mice.	C3 C5	3.03e-06	2	61	2	27109176
Pubmed	Cerebellar mutations affecting the postnatal survival of Purkinje cells in the mouse disclose a longitudinal pattern of differentially sensitive cells.	HERC1 AGTPBP1	3.03e-06	2	61	2	3678603
Pubmed	EIF3C Promotes Lung Cancer Tumorigenesis by Regulating the APP/HSPA1A/LMNB1 Axis.	EIF3C EIF3CL	3.03e-06	2	61	2	36157221
Pubmed	Novel evidence that crosstalk between the complement, coagulation and fibrinolysis proteolytic cascades is involved in mobilization of hematopoietic stem/progenitor cells (HSPCs).	C3 C5	3.03e-06	2	61	2	24667943
Pubmed	The Deubiquitinase USP9X Maintains DNA Replication Fork Stability and DNA Damage Checkpoint Responses by Regulating CLASPIN during S-Phase.	USP9X CLSPN	3.03e-06	2	61	2	26921344
Pubmed	Complement decay-accelerating factor inhibits inflammation-induced myopia development.	C3 C5	3.03e-06	2	61	2	38795684
Pubmed	Genetic variants of C5 and polymorphisms of C3 in Chinese patients with paroxysmal nocturnal hemoglobinuria.	C3 C5	3.03e-06	2	61	2	27307199
Pubmed	The proinflammatory mediators C3a and C5a are essential for liver regeneration.	C3 C5	3.03e-06	2	61	2	12975457
Pubmed	The role of the complement anaphylatoxins in the recruitment of eosinophils.	C3 C5	3.03e-06	2	61	2	18039528
Pubmed	Complement anaphylatoxins C3a and C5a: Emerging roles in cancer progression and treatment.	C3 C5	3.03e-06	2	61	2	29155219
Pubmed	Complement C3 variant and the risk of age-related macular degeneration.	C3 C5	3.03e-06	2	61	2	17634448
Pubmed	Targeting complement component 5a promotes vascular integrity and limits airway remodeling.	C3 C5	3.03e-06	2	61	2	23530212
Pubmed	Plasma levels of complement activation fragments C3b and sC5b-9 significantly increased in patients with thrombotic microangiopathy after allogeneic stem cell transplantation.	C3 C5	3.03e-06	2	61	2	28801815
Pubmed	Expression and characterization of the C345C/NTR domains of complement components C3 and C5.	C3 C5	3.03e-06	2	61	2	14662858
Pubmed	C3a and C5a promote renal ischemia-reperfusion injury.	C3 C5	3.03e-06	2	61	2	22797180
Pubmed	Generation of C5a in the absence of C3: a new complement activation pathway.	C3 C5	3.03e-06	2	61	2	16715088
Pubmed	Functions of the complement components C3 and C5 during sepsis.	C3 C5	3.03e-06	2	61	2	18587006
Pubmed	Integrated genomic profiling identifies candidate genes implicated in glioma-genesis and a novel LEO1-SLC12A1 fusion gene.	SLC12A1 LEO1	3.03e-06	2	61	2	20196086
Pubmed	Complement C3 and C5 deficiency affects fracture healing.	C3 C5	3.03e-06	2	61	2	24260573
Pubmed	METTL3 protects METTL14 from STUB1-mediated degradation to maintain m6 A homeostasis.	SRPK1 NCBP1 EIF3C HERC1 EIF3CL TFRC	3.29e-06	231	61	6	36597993
Pubmed	Human transcription factor protein interaction networks.	PCF11 LHX1 TCF4 CCDC8 TADA1 ZFHX4 ATRX USP9X DDX18 EIF3C HERC1 TFRC	5.95e-06	1429	61	12	35140242
Pubmed	Complement-mediated inhibition of neovascularization reveals a point of convergence between innate immunity and angiogenesis.	C3 C5	9.07e-06	3	61	2	20625009
Pubmed	Complement serves as a switch between CD4+ T cell-independent and -dependent RBC antibody responses.	C3 C5	9.07e-06	3	61	2	30429364
Pubmed	Alterations in gene expression of complement components in chronic rhinosinusitis.	C3 C5	9.07e-06	3	61	2	20109314
Pubmed	Carboxypeptidase B2 and N play different roles in regulation of activated complements C3a and C5a in mice.	C3 C5	9.07e-06	3	61	2	29383821
Pubmed	C1q acts in the tumour microenvironment as a cancer-promoting factor independently of complement activation.	C3 C5	9.07e-06	3	61	2	26831747
Pubmed	Expression of complement C3, C5, C3aR and C5aR1 genes in resting and activated CD4+ T cells.	C3 C5	9.07e-06	3	61	2	30612786
Pubmed	Complement-dependent acute-phase expression of C-reactive protein and serum amyloid P-component.	C3 C5	9.07e-06	3	61	2	10878380
Pubmed	Carboxypeptidase B2 deficiency reveals opposite effects of complement C3a and C5a in a murine polymicrobial sepsis model.	C3 C5	9.07e-06	3	61	2	25851247
Pubmed	Differential contributions of C3, C5, and decay-accelerating factor to ethanol-induced fatty liver in mice.	C3 C5	9.07e-06	3	61	2	17383432
Pubmed	Complement system is activated in stenotic aortic valves.	C3 C5	9.07e-06	3	61	2	17498719
Pubmed	Complement component C3 mediates inflammatory injury following focal cerebral ischemia.	C3 C5	9.07e-06	3	61	2	16778128
Pubmed	Chromosomal locations and gonadal dependence of genes that mediate resistance to ectromelia (mousepox) virus-induced mortality.	C3 C5	9.07e-06	3	61	2	2002550
Pubmed	Long-term sublingual immunotherapy for Japanese cedar pollinosis and the levels of IL-17A and complement components 3a and 5a.	C3 C5	9.07e-06	3	61	2	25934649
Pubmed	Antigen-presenting cell-derived complement modulates graft-versus-host disease.	C3 C5	9.07e-06	3	61	2	22585573
Pubmed	Complement Component 3 Negatively Regulates Antibody Response by Modulation of Red Blood Cell Antigen.	C3 C5	9.07e-06	3	61	2	29942300
Pubmed	Target neuron controls the integrity of afferent axon phenotype: a study on the Purkinje cell-climbing fiber system in cerebellar mutant mice.	HERC1 AGTPBP1	9.07e-06	3	61	2	7891151
Pubmed	The anti-inflammatory effect of combined complement and CD14 inhibition is preserved during escalating bacterial load.	C3 C5	9.07e-06	3	61	2	25907631
Pubmed	Aspergillus fumigatus conidial metalloprotease Mep1p cleaves host complement proteins.	C3 C5	9.07e-06	3	61	2	30139746
Pubmed	Complement C3 and C3aR mediate different aspects of emotional behaviours; relevance to risk for psychiatric disorder.	C3 C5	9.07e-06	3	61	2	34543680
Pubmed	Complement C5 but not C3 is expendable for tissue factor activation by cofactor-independent antiphospholipid antibodies.	C3 C5	9.07e-06	3	61	2	29716893
Pubmed	Combined inhibition of complement and CD14 efficiently attenuated the inflammatory response induced by Staphylococcus aureus in a human whole blood model.	C3 C5	9.07e-06	3	61	2	24516199
Pubmed	Expression of the complement system's activation factors in plasma of patients with early/late-onset severe pre-eclampsia.	C3 C5	9.07e-06	3	61	2	27461873
Pubmed	Complement component C3 is required for protective innate and adaptive immunity to larval strongyloides stercoralis in mice.	C3 C5	9.07e-06	3	61	2	16547268
Pubmed	Proteome-scale mapping of binding sites in the unstructured regions of the human proteome.	NBPF19 SLC12A1 ZNF532 NBPF9 TSPYL2 CLSPN NBPF14	1.03e-05	430	61	7	35044719
Pubmed	Reciprocal interaction between SIRT6 and APC/C regulates genomic stability.	PCF11 CCDC8 ATRX SUPT6H USP9X DDX18 TSPYL2	1.20e-05	440	61	7	34244565
Pubmed	Phenotypic and Interaction Profiling of the Human Phosphatases Identifies Diverse Mitotic Regulators.	PCF11 CCDC8 LEO1 USP9X GOLIM4 NCBP1 EIF2AK4 EIF3C HERC1 AGTPBP1	1.33e-05	1049	61	10	27880917
Pubmed	Intracellular complement (complosome) is expressed in hematopoietic stem/progenitor cells (HSPCs) and regulates cell trafficking, metabolism and proliferation in an intracrine Nlrp3 inflammasome-dependent manner.	C3 C5	1.81e-05	4	61	2	37055506
Pubmed	Impaired mast cell-dependent natural immunity in complement C3-deficient mice.	C3 C5	1.81e-05	4	61	2	9367154
Pubmed	C3a, C5a renal expression and their receptors are correlated to severity of IgA nephropathy.	C3 C5	1.81e-05	4	61	2	24327134
Pubmed	Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N.	C3 C5	1.81e-05	4	61	2	11939578
Pubmed	Complement C3 activation regulates the production of tRNA-derived fragments Gly-tRFs and promotes alcohol-induced liver injury and steatosis.	C3 C5	1.81e-05	4	61	2	31076642
Pubmed	Complement C5a Receptor 1 Exacerbates the Pathophysiology of N. meningitidis Sepsis and Is a Potential Target for Disease Treatment.	C3 C5	1.81e-05	4	61	2	29362231
Pubmed	A new role of the complement system: C3 provides protection in a mouse model of lung infection with intracellular Chlamydia psittaci.	C3 C5	1.81e-05	4	61	2	23189195
Pubmed	C5 inhibition prevents renal failure in a mouse model of lethal C3 glomerulopathy.	C3 C5	1.81e-05	4	61	2	28139294
Pubmed	Interaction between the Ret finger protein and the Int-6 gene product and co-localisation into nuclear bodies.	EIF3C EIF3CL	1.81e-05	4	61	2	10504338
Pubmed	Levels of complement components iC3b, C3c, C4, and SC5b-9 in peritoneal fluid and serum of infertile women with endometriosis.	C3 C5	1.81e-05	4	61	2	17482181
Pubmed	Early complementopathy after multiple injuries in humans.	C3 C5	1.81e-05	4	61	2	22258234
Pubmed	The development of atypical hemolytic uremic syndrome depends on complement C5.	C3 C5	1.81e-05	4	61	2	21148255
Pubmed	Expressions of C5a and its receptor CD88 after spinal cord injury in C3-deficient mice.	C3 C5	1.81e-05	4	61	2	23033813
Pubmed	Molecular cloning and characterization of the human anaphylatoxin C3a receptor.	C3 C5	1.81e-05	4	61	2	8702752
Pubmed	Automated phosphoproteome analysis for cultured cancer cells by two-dimensional nanoLC-MS using a calcined titania/C18 biphasic column.	NBPF10 EIF3CL	1.81e-05	4	61	2	18187866
Pubmed	Complement activation by recombinant HIV-1 glycoprotein gp120.	C3 C5	1.81e-05	4	61	2	7911492
Pubmed	Complement C3b interactions studied with surface plasmon resonance technique.	C3 C5	1.81e-05	4	61	2	11367533
Pubmed	Complement factors in newly diagnosed Nigerian schizoprenic patients and those on antipsychotic therapy.	C3 C5	1.81e-05	4	61	2	23235303
Pubmed	Variations in the C3, C3a receptor, and C5 genes affect susceptibility to bronchial asthma.	C3 C5	1.81e-05	4	61	2	15278436
Pubmed	Phylogeny of the C3/C4/C5 complement-component gene family indicates that C5 diverged first.	C3 C5	1.81e-05	4	61	2	8015436
Pubmed	Experimentally-induced anti-myeloperoxidase vasculitis does not require properdin, MASP-2 or bone marrow-derived C5.	C3 C5	1.81e-05	4	61	2	27235854
Pubmed	Acetylation of ELF5 suppresses breast cancer progression by promoting its degradation and targeting CCND1.	LEO1 SUPT6H USP9X DDX18 NEMF SRPK1 NCBP1 EIF3C	1.81e-05	653	61	8	33742100
Pubmed	Systematic bromodomain protein screens identify homologous recombination and R-loop suppression pathways involved in genome integrity.	SP100 CHAF1B INTS14 TADA1 ZFHX4 CECR2 DDX18 TSPYL2 CLSPN AGTPBP1	2.27e-05	1116	61	10	31753913
Pubmed	Intranasal peptide-induced tolerance and linked suppression: consequences of complement deficiency.	C3 C5	3.02e-05	5	61	2	25039245
Pubmed	Distinct contributions of complement factors to platelet activation and fibrin formation in venous thrombus development.	C3 C5	3.02e-05	5	61	2	28223279
Pubmed	C5L2 is critical for the biological activities of the anaphylatoxins C5a and C3a.	C3 C5	3.02e-05	5	61	2	17322907
Pubmed	Role of complement receptors 1 and 2 (CD35 and CD21), C3, C4, and C5 in survival by mice of Staphylococcus aureus bacteremia.	C3 C5	3.02e-05	5	61	2	15192652
Pubmed	Drusen complement components C3a and C5a promote choroidal neovascularization.	C3 C5	3.02e-05	5	61	2	16452172
Pubmed	New concepts on the therapeutic control of complement anaphylatoxin receptors.	C3 C5	3.02e-05	5	61	2	28576324
Pubmed	A novel role of complement in retinal degeneration.	C3 C5	3.02e-05	5	61	2	23074214
Pubmed	Complement activation triggers metalloproteinases release inducing cervical remodeling and preterm birth in mice.	C3 C5	3.02e-05	5	61	2	21801872
Pubmed	Structural basis for evolutionarily conserved interactions between TFIIS and Paf1C.	LEO1 SUPT6H	3.02e-05	5	61	2	37696373
Pubmed	Formation of high affinity C5 convertase of the classical pathway of complement.	C3 C5	3.02e-05	5	61	2	12878586
Pubmed	Disruption of the C5a receptor gene increases resistance to acute Gram-negative bacteremia and endotoxic shock: opposing roles of C3a and C5a.	C3 C5	3.02e-05	5	61	2	18063050
Pubmed	Identification of complement activation sites in human immunodeficiency virus type-1 glycoprotein gp120.	C3 C5	3.02e-05	5	61	2	8630395
Pubmed	Chibby interacts with NBPF1 and clusterin, two candidate tumor suppressors linked to neuroblastoma.	NBPF11 NBPF1	3.02e-05	5	61	2	20096688
Interaction	NEK4 interactions	NBPF8 NBPF15 NBPF12 NBPF9 NBPF10 SRPK1 NBPF11 NBPF14 AGTPBP1 NBPF1	7.68e-06	582	60	10	int:NEK4
Interaction	RIT1 interactions	CHAF1B NBPF15 INTS14 SUPT6H USP9X DDX18 NBPF10 NCBP1 ICE1 EIF3C CLSPN NBPF14 EIF3CL TFRC	1.13e-05	1230	60	14	int:RIT1
Cytoband	1q21.1	NBPF8 NBPF9 NBPF10 NBPF11 NBPF14	2.14e-08	62	61	5	1q21.1
Cytoband	Ensembl 112 genes in cytogenetic band chr1q21	NBPF19 NBPF15 NBPF12 NBPF9 NBPF10 NBPF11 NBPF14	1.12e-06	404	61	7	chr1q21
Cytoband	Ensembl 112 genes in cytogenetic band chr1p11	NBPF8 NBPF26	3.59e-04	21	61	2	chr1p11
GeneFamily	Neuroblastoma breakpoint family	NBPF8 NBPF19 NBPF15 NBPF12 NBPF9 NBPF10 NBPF26 NBPF11 NBPF14 NBPF1	1.23e-21	23	41	10	662
GeneFamily	C3 and PZP like, alpha-2-macroglobulin domain containing	C3 C5	1.79e-04	9	41	2	1234
GeneFamily	Cyclins\|Mediator complex	CDK19 MED12L	2.53e-03	33	41	2	1061
GeneFamily	Complement system\|Sushi domain containing	C3 C5	3.01e-03	36	41	2	492
GeneFamily	X-linked mental retardation\|Angiotensin receptors	ATRX USP9X	6.43e-03	53	41	2	103
GeneFamily	Armadillo repeat containing\|Protein phosphatase 1 regulatory subunits	CCDC8 CNST HYDIN	7.96e-03	181	41	3	694
Coexpression	GSE17721_0.5H_VS_12H_POLYIC_BMDC_UP	LHX1 CATSPER1 ZNF532 DDX18 NCBP1 TFRC	7.17e-06	200	61	6	M4084
Coexpression	ACEVEDO_LIVER_CANCER_WITH_H3K27ME3_DN	NBPF15 ZFHX4 EIF3C NBPF11 NBPF14 NBPF1	1.30e-05	222	61	6	M16955
CoexpressionAtlas	Mesoderm Day 5_vs_Endoderm Differentiated Cells-Confounder_removed-fold2.0_adjp0.05	NBPF15 NBPF12 NBPF26 C5 NBPF11 NBPF14 PLCE1	2.88e-05	320	59	7	PCBC_ratio_MESO-5_vs_DE_cfr-2X-p05
CoexpressionAtlas	FacebaseRNAseq_e10.5_Maxillary Arch_top-relative-expression-ranked_500	LHX1 SP100 CATSPER1 SNCAIP ZFHX4 CECR2 CLSPN CNGA1	6.17e-05	492	59	8	Facebase_RNAseq_e10.5_Maxillary Arch_500
CoexpressionAtlas	Mesoderm Day 5_vs_Pluripotent Stem Cells-Confounder_removed-fold2.0_adjp0.05	LHX1 NBPF15 CCDC8 NBPF12 NBPF26 C3 ERICH2 C5 NBPF11 NBPF14 NBPF1 PLCE1	6.48e-05	1153	59	12	PCBC_ratio_MESO-5_vs_SC_cfr-2X-p05
ToppCell	Control-B_intermediate-1\|Control / disease group and sub_cluster of B and Plasma cells(res = 0.5)	NBPF15 NBPF12 NBPF10 ICE1 EIF3C NBPF11 NBPF1 EIF3CL	7.58e-11	167	61	8	948504367ecf58144d9dd74d2ec531358fc4b309
ToppCell	Mild/Remission-B_naive-1\|Mild/Remission / disease group and sub_cluster of B and Plasma cells(res = 0.5)	NBPF15 NBPF10 ICE1 EIF3C NBPF11 NBPF1 EIF3CL	1.07e-09	143	61	7	bd3f5fbd4e9e4dc414682db5607494f3ce988deb
ToppCell	COVID-19_Mild-CD4+_T_activated\|COVID-19_Mild / Disease condition and Cell class	NBPF15 NBPF10 ICE1 EIF3C NBPF11 NBPF1 EIF3CL	5.73e-09	182	61	7	877b6e611626628e709568747512f2827ebb2795
ToppCell	Control-B_intermediate-1\|World / disease group and sub_cluster of B and Plasma cells(res = 0.5)	NBPF15 NBPF12 NBPF10 EIF3C NBPF11 NBPF1	4.65e-08	144	61	6	984470ff6ddce4c743e2db78fa98dae055aaa273
ToppCell	Control-B_naive-1\|World / disease group and sub_cluster of B and Plasma cells(res = 0.5)	NBPF15 NBPF10 ICE1 EIF3C NBPF11 NBPF1	7.20e-08	155	61	6	0a78d1cab2bdba2dc8a74cdf35b5a0192370c4b5
ToppCell	Control-B_naive-1\|Control / disease group and sub_cluster of B and Plasma cells(res = 0.5)	NBPF15 NBPF10 ICE1 EIF3C NBPF11 NBPF1	1.29e-07	171	61	6	d18855b24aadea38fd1e4592f945cf15b85e05f1
ToppCell	Anterior_Cingulate_gyrus_(CgG)-Non-neuronal-Macroglial-Astro-Astrocyte\|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	ZFHX4 CECR2 NBPF10 NBPF26 NBPF14	5.79e-06	187	61	5	dd1d91f101b837bba513f77defa6e6902b2c0570
ToppCell	Anterior_Cingulate_gyrus_(CgG)-Non-neuronal-Macroglial-Astro-Astrocyte-Astro_L1-6_FGFR3_ETNPPL\|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	ZFHX4 CECR2 NBPF10 NBPF26 NBPF14	5.79e-06	187	61	5	4d2115a05ec36dd179ca1d4a525f2d4501aea557
ToppCell	Anterior_Cingulate_gyrus_(CgG)-Non-neuronal-Macroglial-Astro\|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	ZFHX4 CECR2 NBPF10 NBPF26 NBPF14	5.79e-06	187	61	5	ae90c263f80c36a410150d499e268d198944a3d9
ToppCell	COPD-Myeloid-cMonocyte\|COPD / Disease state, Lineage and Cell class	NBPF19 NBPF10 NBPF26 NBPF14 AGTPBP1	6.10e-06	189	61	5	d29f3a0bd23e6eb46389e6eb7ef21851c7b57545
ToppCell	COPD-Myeloid-cMonocyte\|Myeloid / Disease state, Lineage and Cell class	XYLT1 NBPF19 NBPF26 NBPF14 AGTPBP1	6.10e-06	189	61	5	6294691231c7d38707323cf31578a107d3b2c622
ToppCell	COPD-Myeloid-ncMonocyte\|World / Disease state, Lineage and Cell class	XYLT1 NBPF19 NBPF26 NBPF14 AGTPBP1	6.26e-06	190	61	5	aece860b5609ad5a8fc920d685f0d0ec71bf9018
ToppCell	COPD-Myeloid-ncMonocyte\|Myeloid / Disease state, Lineage and Cell class	XYLT1 NBPF19 NBPF26 NBPF14 AGTPBP1	6.26e-06	190	61	5	ed978cd5d9da87b49878a330e362762c487f849f
ToppCell	Control-Myeloid-ncMonocyte\|Control / Disease state, Lineage and Cell class	XYLT1 NBPF19 NBPF26 NBPF14 AGTPBP1	7.10e-06	195	61	5	fcb05948e7480dc53f06f3fc9b9c3fc129874edd
ToppCell	5'-Adult-SmallIntestine-Epithelial-Tuft-related-BEST4+_epithelial\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	NBPF19 NBPF10 NBPF26 C5 CNGA1	7.10e-06	195	61	5	e87b11e3242fdbed2e7f383e6876ec375af32bd4
ToppCell	Control-Myeloid-ncMonocyte\|World / Disease state, Lineage and Cell class	XYLT1 NBPF19 NBPF26 NBPF14 AGTPBP1	7.10e-06	195	61	5	b4444b67a709e82b8e2ee510924c3152cb88b051
ToppCell	Neuronal-Excitatory-eC(RORB)-eC_1-CARM1P1--L3-4\|Neuronal / cells hierarchy compared to all cells using T-Statistic	NBPF19 NBPF10 GOLIM4 NBPF26 NBPF14	8.02e-06	200	61	5	47791c93d03ee17c1ce17e27f075be4fc6f2590e
ToppCell	Neuronal-Excitatory-eC(RORB)-eC_1-CARM1P1\|Neuronal / cells hierarchy compared to all cells using T-Statistic	NBPF19 NBPF10 GOLIM4 NBPF26 NBPF14	8.02e-06	200	61	5	f75d95376a340d467c4392b872b2a2dbdd184556
ToppCell	Neuronal-Excitatory-eC(RORB)-eC_1-CARM1P1-\|Neuronal / cells hierarchy compared to all cells using T-Statistic	NBPF19 NBPF10 GOLIM4 NBPF26 NBPF14	8.02e-06	200	61	5	fae26560ba3b0b638b6bcf92f05330824b31d21b
ToppCell	343B-Lymphocytic-CD8+_Cytotoxic_T-cell-CD8+_Cytotoxic_T_cell_0\|343B / Donor, Lineage, Cell class and subclass (all cells)	XYLT1 NBPF19 SP100 MED12L	5.48e-05	151	61	4	78475027bba9e3026e42493fec8ea630972353bb
ToppCell	Severe-B_naive-1\|Severe / disease group and sub_cluster of B and Plasma cells(res = 0.5)	NBPF15 NBPF10 ICE1 NBPF1	6.70e-05	159	61	4	2881b054bbeb479221ee3c38bbd9b0815b123579
ToppCell	facs-Marrow-B-cells-24m-Lymphocytic-precursor_B_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SLC12A1 ZFHX4 CECR2 HYDIN	6.86e-05	160	61	4	c381ec6be8cf887861cc18f831a20db42f953fe1
ToppCell	PBMC-Control-Lymphocyte-B-B_cell-B_intermediate-B_intermediate-1\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	TCF4 NBPF10 EIF3C NBPF11	6.86e-05	160	61	4	7ad065337ac802de52c15ee715f6b78a3eed0cef
ToppCell	facs-Marrow-B-cells-24m-Lymphocytic-pre_B_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SLC12A1 ZFHX4 CECR2 HYDIN	6.86e-05	160	61	4	25c8f3d2a6d14ff0ca0b965fce89d3ff22f40585
ToppCell	facs-Trachea-24m-Mesenchymal-fibroblast-fibroblast_of_trachea-tracheal_fibroblast_l20-1\|24m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	CCDC8 C3 EIF2AK4 HYDIN	7.20e-05	162	61	4	56f1789e69a6cb29956e46aba92b290847327c1f
ToppCell	PND03-Immune-Immune_Lymphocytic_T/NK-Lymphocytic_T-CD8_T-CD8_T_prolif\|PND03 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	SP100 SRPK1 NCBP1 CLSPN	8.29e-05	168	61	4	ade02beb8d663fce4be2aefa10392ab849a4bbe7
ToppCell	PBMC-Severe-Myeloid-cDC-cDC-cDC_12\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	GOLIM4 EIF2AK4 CLSPN EPB41L2	9.29e-05	173	61	4	a55f310c533432e9e26e400026a5b47245152976
ToppCell	PBMC-Severe-Myeloid-cDC-cDC-cDC_12\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	GOLIM4 EIF2AK4 CLSPN EPB41L2	9.29e-05	173	61	4	9c7386bf0a899882c733f0b4921a96afde032a7d
ToppCell	3'-Pediatric_IBD-SmallIntestine-Mesenchymal-fibroblastic-Stromal_3_(C7+)\|Pediatric_IBD / Celltypes from developing, pediatric, Crohn's, & adult GI tract	CCDC8 TMEM31 C3 EPB41L2	1.06e-04	179	61	4	dcd0a83f0592ae27f814d064b4791f84c3c86e64
ToppCell	3'-Child09-12-SmallIntestine-Epithelial-Tuft-related-BEST4+_epithelial\|Child09-12 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	NBPF19 NBPF9 NBPF10 NBPF26	1.08e-04	180	61	4	b234668bf181522807470e396792e1b54890b719
ToppCell	COVID-19_Convalescent\|World / Disease condition and Cell class	NBPF19 NBPF15 NBPF26 NBPF14	1.11e-04	181	61	4	a62115a8da486fc61225901c72b1ec70bcaf4c36
ToppCell	10x5'-Liver-Lymphocytic_T_CD4-T_CD4/CD8\|Liver / Manually curated celltypes from each tissue	NBPF15 TSPYL2 HERC1 TFRC	1.11e-04	181	61	4	f2315414e714ac86211546a935660c4be6e85f1b
ToppCell	COVID-19_Mild-NK_activated\|COVID-19_Mild / Disease condition and Cell class	NBPF10 ICE1 EIF3C EIF3CL	1.15e-04	183	61	4	22bd05135906d0ecc4ba8c2e0a666093d1bf3b8f
ToppCell	LPS-antiTNF-Epithelial_alveolar-AT_1-AT2_Progenitor\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	CECR2 C3 ERICH2 C5	1.18e-04	184	61	4	7cc5796557379c3d1db078c1aeda40659c6e401c
ToppCell	COPD-Myeloid-cMonocyte\|World / Disease state, Lineage and Cell class	NBPF19 NBPF26 NBPF14 AGTPBP1	1.18e-04	184	61	4	ceec41ed5636032aaf7716d1203816ea58bd39bd
ToppCell	Primary_Visual_cortex_(V1C)-Neuronal-Glutamatergic_Excit-Glut_C-D_(RORB)-Glut_C_(IT_L4_RORB)-Exc_L4_RORB_CACNG5\|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	NBPF19 TADA1 NBPF10 NBPF14	1.18e-04	184	61	4	658f2e522055e88c92bc482a845c40f8f5f1a8e3
ToppCell	Mid-temporal_gyrus_(MTG)-Non-neuronal-Macroglial-Oligo-OPC-OPC_L1-6_MYT1\|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	XYLT1 ZFHX4 CECR2 PLCE1	1.20e-04	185	61	4	2e1766f1a972fecd670daaaf7eb2d3a404f121e7
ToppCell	Mid-temporal_gyrus_(MTG)-Non-neuronal-Macroglial-Oligo-OPC\|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	XYLT1 ZFHX4 CECR2 PLCE1	1.20e-04	185	61	4	7aaa8335b40927e3e8fdcede807cd521fc213a0d
ToppCell	356C-Lymphocytic-CD4_T-cell-Treg_cell_3\|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells)	NBPF26 FAM114A2 NCBP1 EIF3C	1.25e-04	187	61	4	c8278525b3e1d3f3f4defcaf109cce22dd2e157a
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Endothelial-blood_vessel_endothelial_cell_of_kidney-capillary-immature_endothelial_cell-Peritubular_Capilary_Endothelial_Cell__prolif\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	TCF4 CHAF1B SNCAIP CLSPN	1.25e-04	187	61	4	35c382c0aabd46906113e5db30ea24bb8e658899
ToppCell	Mid-temporal_gyrus_(MTG)-Non-neuronal-Macroglial-Astro\|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	ZFHX4 NBPF10 NBPF26 NBPF14	1.25e-04	187	61	4	5d3d68519c8e19f10c29f9d81712125be78ca15a
ToppCell	Mid-temporal_gyrus_(MTG)-Non-neuronal-Macroglial-Astro-Astrocyte\|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	ZFHX4 NBPF10 NBPF26 NBPF14	1.25e-04	187	61	4	5c73010fe4c85fb5cc1273f5504821229ca0cc4b
ToppCell	Mid-temporal_gyrus_(MTG)-Non-neuronal-Macroglial-Astro-Astrocyte-Astro_L1-6_FGFR3_ETNPPL\|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	ZFHX4 NBPF10 NBPF26 NBPF14	1.25e-04	187	61	4	93c78fc7f126132eb84feb47be2c4e8c568b9e91
ToppCell	LPS-IL1RA-Epithelial_alveolar\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	CECR2 C3 ERICH2 C5	1.28e-04	188	61	4	6164d467b612767ceba15de34176bcc8e8c36ab8
ToppCell	Endothelial-B-IPF_03\|World / lung cells shred on cell class, cell subclass, sample id	TCF4 CHAF1B NBPF9 EIF3C	1.28e-04	188	61	4	ecb74d67314a43b5805b7f2a7bb9ff6c5a60200a
ToppCell	Smart-start-Cell-Wel_seq-Neoplastic-Stem-like-OPC-like-OPC-like_Prolif-E\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	DDX18 GOLIM4 C5 CLSPN	1.28e-04	188	61	4	0476d7ee3e0ce78c3c5b111e9ade01098f9ea7ec
ToppCell	356C-Lymphocytic-CD4_T-cell-Treg_cell_3\|CD4_T-cell / Donor, Lineage, Cell class and subclass (all cells)	NBPF26 FAM114A2 NCBP1 EIF3C	1.31e-04	189	61	4	99b01893da9f9f7c9528afaffad178285211738b
ToppCell	LPS-IL1RA-Epithelial_alveolar-AT_1-AT2_Progenitor\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	CECR2 C3 ERICH2 C5	1.31e-04	189	61	4	5f883ef4cc0383142d538ae61f4fb40dfdb8ef18
ToppCell	Somatosensory_Cortex_(S1)-Non-neuronal-Macroglial-Astro\|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	ZFHX4 NBPF10 NBPF26 NBPF14	1.33e-04	190	61	4	3a55cc5dc2549788bfe55f649686887b21a1fdd2
ToppCell	Somatosensory_Cortex_(S1)-Non-neuronal-Macroglial-Astro-Astrocyte\|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	ZFHX4 NBPF10 NBPF26 NBPF14	1.33e-04	190	61	4	1c3d601422efa60fad8565f9ccd9032b847e4a91
ToppCell	Smart-start-Cell-Wel_seq-Non-neoplastic-Myeloid-TAM-BDM-TAM-BDM_INF-G\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	MED12L C3 CNGA1 EPB41L2	1.39e-04	192	61	4	935a4a36881a9fa4daa02cba96af07f6686ed8d6
ToppCell	RV-01._Fibroblast_I\|RV / Chamber and Cluster_Paper	XYLT1 TCF4 C3 EPB41L2	1.39e-04	192	61	4	356160b113c3305a61ceeaff33ce3c9da0be2878
ToppCell	PBMC_fresh-frozen-Mild-Moderate_progression_d02_child\|PBMC_fresh-frozen / Compartment, severity and other cell annotations on 10x 3' data (130k)	TCF4 TP53INP1 TSPYL2 HERC1	1.39e-04	192	61	4	aee6522d25e012231cdb905ce047295cb64d6e82
ToppCell	ILEUM-inflamed-(7)_Endothelial_cell-(7)_Lymphatics\|(7)_Endothelial_cell / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2)	CHAF1B SNCAIP ZFHX4 EPB41L2	1.39e-04	192	61	4	d43caf42ec744e895137f31ef65a990e250669d2
ToppCell	Smart-start-Cell-Wel_seq-Neoplastic-Differentiated-like-AC-like-AC-like_Prolif-G\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	TMEM31 C5 CLSPN HYDIN	1.39e-04	192	61	4	d6f656be2698bd215717d35f4e7ab727c08c61e0
ToppCell	COPD-Myeloid-ncMonocyte\|COPD / Disease state, Lineage and Cell class	NBPF19 NBPF26 NBPF14 AGTPBP1	1.41e-04	193	61	4	936ca95995599356b794fba32bfd82d8de339365
ToppCell	IIH-mono3-\|IIH / Condition, Cell_class and T cell subcluster	CECR2 GOLIM4 C3 EPB41L2	1.47e-04	195	61	4	28a858b04a7b413916c07a8d880f5ea02e985461
ToppCell	IIH-mono3\|IIH / Condition, Cell_class and T cell subcluster	CECR2 GOLIM4 C3 EPB41L2	1.47e-04	195	61	4	c6dd5af582d257be64b718e30f60220c1bf1738a
ToppCell	COVID-19-kidney-Fibroblast-2\|COVID-19 / Disease (COVID-19 only), tissue and cell type	XYLT1 SNCAIP ZFHX4 EPB41L2	1.47e-04	195	61	4	3d62ce1c696f47d4d7eb0c5bb0eec2c24b122bb2
ToppCell	Neuron-Postmitotic-Excitatory_Neuron_-IPC/newborn-38\|World / Primary Cells by Cluster	TCF4 SNCAIP ZFHX4 ATRX	1.50e-04	196	61	4	38da0751941adca650fe9b383d9f343153978eb5
ToppCell	Neuron-Postmitotic-Excitatory_Neuron_-IPC/newborn\|World / Primary Cells by Cluster	TCF4 SNCAIP ZFHX4 ATRX	1.50e-04	196	61	4	721650a08d260faf530dbd52d4e9275d27f3bac2
ToppCell	Parenchymal-NucSeq-Stromal-Pericyte-Muscle_pericyte_pulmonary\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	XYLT1 TCF4 EPB41L2 PLCE1	1.53e-04	197	61	4	f66945f9007d59d4208849c7fd727f8519713fbc
ToppCell	LPS_anti-TNF-Epithelial_alveolar-AT_2-Differentiating_AT2\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	TSPYL2 C3 C5 TFRC	1.53e-04	197	61	4	1485933986921ff45669d9b7501c8d17050b3e97
ToppCell	Parenchymal-NucSeq-Stromal-Pericyte\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	XYLT1 TCF4 EPB41L2 PLCE1	1.53e-04	197	61	4	41dd312f46a2b983c8d864adeb6970c0ca4a8048
ToppCell	H1299-infected-SARSCoV2\|infected / Cell line, Condition and Strain	ATRX DDX18 NEMF CLSPN	1.53e-04	197	61	4	0fa3e4cf93e77d78b1f97b906c5b13ca741ae17e
ToppCell	Control-Control-Lymphocyte-T/NK-NK_activated\|Control / Disease, condition lineage and cell class	SUPT6H GOLIM4 HERC1 EIF3CL	1.56e-04	198	61	4	76d5fe4e5bbe6c73a6ca409b80b5c3924e07cab7
ToppCell	LPS_IL1RA-Epithelial_alveolar-AT_2-Differentiating_AT2\|LPS_IL1RA / Treatment groups by lineage, cell group, cell type	CECR2 TSPYL2 C3 C5	1.56e-04	198	61	4	285f729140b1df029c24f6ca1d2438470ac51794
ToppCell	Parenchymal-NucSeq-Endothelial-Endothelia_lymphatic\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	TCF4 SNCAIP ZFHX4 EPB41L2	1.56e-04	198	61	4	9ab0db78394e730f6866b2db80047149024ad5f6
ToppCell	Parenchymal-NucSeq-Endothelial-Endothelia_lymphatic-Endothelia_Lymphatic\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	TCF4 SNCAIP ZFHX4 EPB41L2	1.56e-04	198	61	4	e47d0e2c6353315c85d7007742bb16b0f05795ed
ToppCell	mild-low-quality_cells\|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	SP100 ATRX TSPYL2 HERC1	1.59e-04	199	61	4	f0b0097df0026496470a80d8cc9375ffd8389b00
ToppCell	LPS_IL1RA_TNF-Epithelial_alveolar-AT_2-Differentiating_AT2\|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type	CECR2 TSPYL2 C3 C5	1.62e-04	200	61	4	e8db082aa4d0597500e4f16a5c0ea3e62c6c59ae
ToppCell	Control_saline-Epithelial_alveolar-AT_1-Differentiating_AT2\|Control_saline / Treatment groups by lineage, cell group, cell type	CECR2 TSPYL2 C3 C5	1.62e-04	200	61	4	eac33be484dc443794e66e473f03e98406c2983e
ToppCell	COVID-19-COVID-19_Mild-Lymphocyte-T/NK-NK_activated\|COVID-19_Mild / Disease, condition lineage and cell class	SP100 NBPF10 EIF3C EIF3CL	1.62e-04	200	61	4	2281debd86e5d92e8fe0397aec9ef670800f7471
ToppCell	Neuronal-Excitatory-eA(LAMP5_LINC00507)\|Neuronal / cells hierarchy compared to all cells using T-Statistic	MED12L NBPF11 HYDIN EPB41L2	1.62e-04	200	61	4	0f23e72649a274043bf23e0952a9b5707c516acf
ToppCell	mild-B_naive\|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	TCF4 SP100 TP53INP1 EPB41L2	1.62e-04	200	61	4	222789b897e2a683bbfd1d00b6fd8705015d90df
Drug	Pesticides	NBPF8 NBPF15 NBPF12 NBPF9 NBPF10 NBPF11 NBPF14 NBPF1	4.27e-09	150	58	8	ctd:D010575
Disease	factor VIII deficiency (is_marker_for)	C3 C5	1.89e-05	4	53	2	DOID:12134 (is_marker_for)
Disease	Lupus Erythematosus, Discoid	TSPYL2 C5	3.15e-05	5	53	2	C0024138
Disease	paroxysmal nocturnal hemoglobinuria (is_implicated_in)	C3 C5	4.73e-05	6	53	2	DOID:0060284 (is_implicated_in)
Disease	Antibody Deficiency Syndrome	C3 C5	4.23e-04	17	53	2	C0003257
Disease	obesity (implicated_via_orthology)	TCF4 ZFHX4 MED12L C3	6.07e-04	215	53	4	DOID:9970 (implicated_via_orthology)
Disease	Immunologic Deficiency Syndromes	C3 C5	7.82e-04	23	53	2	C0021051
Disease	adult respiratory distress syndrome (is_marker_for)	C3 C5	1.00e-03	26	53	2	DOID:11394 (is_marker_for)
Disease	Complement deficiency disease	C3 C5	1.61e-03	33	53	2	C0272242

Protein segments in the cluster

Peptide	Gene	Start	Entry
KEIENANTNNPSADE	nan	486	A8MVM7
EDDDEDSNPKKNTQA	ERICH2	51	A1L162
EDDPEEKGDKNQQQQ	CDK19	361	Q9BWU1
VPEKAQNEADTNNAD	CATSPER1	6	Q8NEC5
FDNEDENSKSQNQDE	EIF2AK4	761	Q9P2K8
NDNKEPEQIAFQDED	CHAF1B	96	Q13112
WPEEDECQDEENQKQ	C3	1631	P01024
ENETENEDDLDQNFK	AGTPBP1	381	Q9UPW5
NEDDLDQNFKNDDIE	AGTPBP1	386	Q9UPW5
PENSEAQEPENDQAE	CECR2	961	Q9BXF3
DNDDEKQNSDDEEQP	LEO1	221	Q8WVC0
KQNSDDEEQPQLSDE	LEO1	226	Q8WVC0
NQNKDNQEVAPNDEA	MED12L	491	Q86YW9
LKDVPNPNQDDDDDE	NCBP1	521	Q09161
PHDDKEEQDLDQQGN	NEMF	961	O60524
DNENEETPQGTNEEK	PPP1R2C	166	O14990
SNNDDEDLTPEQKAE	TCF4	546	P15884
EIDQQAEESDPAQQA	HERC1	2616	Q15751
AENQQNQSSDPEEEK	EPB41L2	31	O43491
VSDKEAGSNENDDQN	LHX1	161	P48742
ETENNVEKPDNDEDE	DDX18	146	Q9NVP1
VQKLSPENDNDDDED	NBPF1	701	Q3BBV0
ENTDDKNNDGEEQEV	GOLIM4	646	O00461
EEDQNEDQDVPDLTN	PCF11	1306	O94913
QNPEQSADEDAEKNE	EIF3C	161	Q99613
QNPEQSADEDAEKNE	EIF3CL	161	B5ME19
QDEEGDEENKNQQGE	CCDC82	301	Q8N4S0
QNEENPGDEEAKNQV	ATRX	1306	P46100
QDQEDSEGDNSKDPD	HYDIN	2436	Q4G0P3
EQQDAPDDSQKNLGD	ICE1	1121	Q9Y2F5
NANADDSQENDEPCK	C5	656	P01031
DDNEDENSANQIAGK	INTS14	291	Q96SY0
NEEGEKQSEAENTEQ	FAM114A2	351	Q9NRY5
DVNKQEEKNEDHTPN	EQTN	36	Q9NQ60
EEAADNQRAEAPADQ	CCDC8	361	Q9H0W5
DEEAAEVNANEQPEA	CNST	151	Q6PJW8
DDAQNQNQPKADKDE	PRR14L	1426	Q5THK1
GDEKQDNESNVDPRD	USP9X	1601	Q93008
GAQQFVAKDPQDDDD	TADA1	121	Q96BN2
QKLSPENDNDDDEDV	NBPF8	396	Q3BBV2
QKLSPENDNDDDEDV	NBPF9	431	P0DPF3
QKLSPENDNDDDEDV	NBPF10	431	Q6P3W6
QKLSPENDNDDDEDV	NBPF11	431	Q86T75
VQKLSPENDNDDDED	NBPF12	701	Q5TAG4
QKLSPENDNDDDEDV	NBPF14	91	Q5TI25
KLSPENDNDDDEDVQ	NBPF15	161	Q8N660
KLSPENDNDDDEDVQ	NBPF19	161	A0A087WUL8
QKLSPENDNDDDEDV	NBPF26	91	B4DH59
SDPQDINEQEESEVN	PLCE1	1121	Q9P212
NANPRPANNEEEEDE	PLCE1	1571	Q9P212
PETLENNESDDQKNQ	SNCAIP	86	Q9Y6H5
DEQAENKEDDQAGVV	SLC12A1	161	Q13621
EDEQEQEHNGPLDNK	SRPK1	456	Q96SB4
AVDEEENADNNTKAN	TFRC	41	P02786
FNVNNSSNKDQEPEE	CNGA1	86	P29973
TKNQEDDVEQPFNDS	CLSPN	191	Q9HAW4
EEENLDDQDEQGNLK	SUPT6H	41	Q7KZ85
NNSNAPNEDQEEEIQ	TMEM31	16	Q5JXX7
GEDNQQENKPSHEDE	ZNF532	1241	Q9HCE3
DQPQNSNDASETKED	ZFHX4	3306	Q86UP3
NNENSVPKDFENVDN	XYLT1	151	Q86Y38
DNNESADDNNENPED	TSPYL2	506	Q9H2G4
ADDNNENPEDNNKNT	TSPYL2	511	Q9H2G4
ENPEDNNKNTDDNEE	TSPYL2	516	Q9H2G4
SSNQEPEFNEKEDDE	TP53INP1	16	Q96A56
NDNPLESNDEKEGQE	SP100	356	P23497
QLENGEAPEENENEE	ZBTB17	256	Q13105